These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31285927)

  • 1. Efficacy and safety of intradetrusor onabotulinumtoxinA injection for managing paediatric non-neurogenic overactive bladder: A prospective case-series study.
    El-Dakhakhny AS; El-Karamany TM; El-Atrebi M; Gharib T
    Arab J Urol; 2019; 17(2):143-149. PubMed ID: 31285927
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in Turkish population.
    Onem K; Bayrak O; Demirtas A; Coskun B; Dincer M; Kocak I; Onur R;
    Neurourol Urodyn; 2018 Jan; 37(1):263-268. PubMed ID: 28407394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder.
    Jiang YH; Kuo HC
    Neurourol Urodyn; 2017 Feb; 36(2):338-343. PubMed ID: 26575613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia.
    Chughtai B; Dunphy C; Lee R; Lee D; Sheth S; Marks L; Kaplan SA; Te AE
    Can J Urol; 2014 Apr; 21(2):7217-21. PubMed ID: 24775575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.
    Hsiao SM; Lin HH; Kuo HC
    PLoS One; 2016; 11(1):e0147137. PubMed ID: 26824901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and Safety of Intradetrusor OnabotulinumtoxinA Injection for Neurogenic Detrusor Overactivity and Overactive Bladder Patients in Taiwan-A Phase IV Prospective, Interventional, Multiple-Center Study (Restore Study).
    Wang CC; Chou EC; Chuang YC; Lin CC; Hsu YC; Liao CH; Kuo HC
    Toxins (Basel); 2021 Dec; 13(12):. PubMed ID: 34941748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis.
    Jo JK; Kim KN; Kim DW; Kim YT; Kim JY; Kim JY
    World J Urol; 2018 Feb; 36(2):305-317. PubMed ID: 29124347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis--Different Mechanisms of Action of Botox on Bladder Dysfunction?
    Kuo YC; Kuo HC
    Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26999201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of spinal cord-injury level on the outcome of neurogenic bladder treatment using OnabotulinumtoxinA.
    Al Taweel W; Alzyoud KM
    Urol Ann; 2015; 7(3):320-4. PubMed ID: 26229318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trigonal-Sparing vs. Trigonal-Involved OnabotulinumtoxinA Injection for the Treatment of Overactive Bladder: A Systematic Review and Meta-Analysis.
    Cui Y; Cai T; Dong T; Zhang X; Zhou Z; Lu Y; Zhang Y; Wu J; Gao Z; Wang Y; Dong L
    Front Neurol; 2021; 12():651635. PubMed ID: 34690904
    [No Abstract]   [Full Text] [Related]  

  • 12. Overactivity index: A noninvasive and objective outcome measure in overactive bladder in children.
    Abdovic S; Colic M; Stemberger Maric L; Cuk M; Hizar I; Milosevic M
    J Pediatr Urol; 2022 Jun; 18(3):352.e1-352.e7. PubMed ID: 35474164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
    Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twelve Months Follow-up of Injection of OnabotulinumtoxinA into Vesical Submucosa for Refractory Non-neurogenic Overactive Bladder.
    Okamura K; Takei M; Nojiri Y; Otsuka A; Takamoto H; Maeda Y; Fujimura T; Yokoyama T; Gotoh M; Homma Y
    Low Urin Tract Symptoms; 2013 May; 5(2):55-9. PubMed ID: 26663370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trigonal-sparing versus trigonal-involved Botox injection for treatment of idiopathic overactive bladder: A randomized clinical trial.
    El-Hefnawy AS; Elbaset MA; Taha DE; Wadie BS; Kenawy M; Shokeir AA; Badry ME
    Low Urin Tract Symptoms; 2021 Jan; 13(1):22-30. PubMed ID: 32543080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preserved micturition after intradetrusor onabotulinumtoxinA injection for treatment of neurogenic bladder dysfunction in Parkinson's disease.
    Knüpfer SC; Schneider SA; Averhoff MM; Naumann CM; Deuschl G; Jünemann KP; Hamann MF
    BMC Urol; 2016 Sep; 16(1):55. PubMed ID: 27596481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson's disease.
    Vurture G; Peyronnet B; Feigin A; Biagioni MC; Gilbert R; Rosenblum N; Frucht S; Di Rocco A; Nitti VW; Brucker BM
    Neurourol Urodyn; 2018 Nov; 37(8):2669-2677. PubMed ID: 29767449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prospective study of the clinical and urodynamic results of intradetrusor botulinum toxin injections for the treatment of neurogenic overactive bladder].
    Bentaleb Y; Castel-Lacanal E; Sallusto F; De Boissezon X; Malavaud B; Marque P; Rischmann P; Gamé X
    Prog Urol; 2008 Jul; 18(7):449-55. PubMed ID: 18602606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effectiveness of transcutaneous electrical neural stimulation therapy in patients with urinary incontinence resistant to initial medical treatment or biofeedback.
    Tugtepe H; Thomas DT; Ergun R; Kalyoncu A; Kaynak A; Kastarli C; Dagli TE
    J Pediatr Urol; 2015 Jun; 11(3):137.e1-5. PubMed ID: 25824876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can botox improve night-time overactive bladder symptoms in women?
    Miotla P; Cartwright R; Futyma K; Bogusiewicz M; Skorupska K; Winkler I; Rechberger T
    Neurourol Urodyn; 2017 Mar; 36(3):648-652. PubMed ID: 26915654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.